»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ %<dvd
IB
g2RrBK,
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 a7Mn/ i.
ztS:1\
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© 5&
2([
1.Antigen presenting cell£¨APC£© w]@H]>sHd
2.Activation induced cell death£¨AICD£© xdLMy#U2
3.Chemokine {{:QtkN
4.Major histocompatibility complex£¨MHC£© o}4~CN9}
5.immunotolerance gPE`mE
kJ'rtz4QO
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© kuq&8f~!
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ nmo<t]
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷ÓÃ
<(Rbu2_
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ }AW"2<@
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿
WrHY'
5.±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌصã \V(w=
4j1$1C{
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© oBS m>V
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ T?g%I
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ tE8aL{<R
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ Q]{ `m
h`n)
b
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ('~}$%C
b!<\#[
A4
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 `nCV
O;B
4{QD: D(D
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ -Hh.8(!XoO
1.Antigenic determinant uXo uN$&
2.IgSF @tIY%;Bgk
3.MBL;¾¶ j4:Xel/
4.chemokine H?_wsh4J
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ |s'5~+
6.TCR-CD3¸´ºÏÎï RsW4 '5
7.FADD£¨Fas-associated protein with death domain£© $(]E$ek
8.AIDS *.6m,QqJ(
9.Tumor rejection antigen /,,IM/(6^
10.AICD /o^/J~/3
>}E
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ x#XxD<y
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© )A$xt)}P!{
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ 3wMnTT"At
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ F!<!)_8Q
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì []$L"?]0uk
6~-,.{Y
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ 9>@Vk
vpY
h])oo:u'/Q
?IG[W+M8
רҵ¿Î ÃâÒßѧ z?@N+||,.
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê }tO>&$
Z6f
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell OtbPrF5
5. Fc¦Å receptor 6. Cytokine -zzoz x]S=
¶þ¡¢ ÎÊ´ðÌâ eQwvp`@"
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØɱÉË°Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 N9s+Tm
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ q8!]x-5$6j
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁÜ°ÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ &`,Y/Cbw
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâЩÌصãµÄÉúÎïѧÒâÒ壿 "d`u#YmR
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦ÓᣠI+,CiJ|4
]_j={0%
~e&O?X
|\>Ifv%{
-Iis/X
w:
S!n?b|_
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ f40OVT@g
s\< @v7A
\XO'7bNu-
רҵ¿Î ÃâÒßѧ >?#zPweA
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê kS?CKd9by
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen Ylyk/
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin =ym<yI<
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test yzMGZi`ut
9. Hybridoma technic 10.Mitogen %@:6&
11.Dentritic cell 12.Immunoproliferation S>)[n]f
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ _u'y7-
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨Äļ¸¸öÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ !
,0
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠ*U}ztH-+/
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ /::Y &&$f
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ hzU(XW
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ V/:2xT
Sfa=AV7K
)\j
dF-s
S;y4Z:!
0qIg:+l+
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ B,&QI&k`~
tj*/%G{Y
-SfU.
XlZl
רҵ¿Î ÃâÒßѧ nt+OaXe5D
Ò»¡¢ Ãû´Ê½âÊÍ #@xB ?u-0q
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï ?
|#dGk
g
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà 2gZ nrU
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ 0AdxV?6z
¶þ¡¢ ÎÊ´ðÌâ Y9>92#aME
1¡¢ TÁÜ°Íϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ x(xi%?G
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁÜ°Íϸ°ûºÍЧӦÎïÖÊ¡£ 3Pllxq<n
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆ乲ͬÌص㼰ÓëÁÙ´²µÄ¹Øϵ¡£ C\aHr!
4¡¢ ºÎνÁÜ°Íϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ A)V*faD
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØϵͳ£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ ,lStT+A
E1tCY.N{
D/~1?p
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ "bDj00nwh
beC%Tnb7
9cUa@;*1
רҵ¿Î ÃâÒßѧ 5 7t.Ud
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê '"\'<>Be
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR 11YJW-V
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA ,ofE*Wt
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM F]P sS(
¶þ¡¢ ÎÊ´ðÌâ iB"ji4[z
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌص㡣
l
EzN
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ 7U_ob"`JV
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖƵÄÒìͬµã¡£ ` =P_ed%&'
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆ书ÄÜ¡£ 8cG`We8l&
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ !5C"`@}q>
;Tp9)UP)
7/51_=%kR
b<~-s sL7a
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ !?0C(VL(:
rMi\#[oB
SFd_k9
רҵ¿Î ÃâÒßѧ `Ucj_6&Tqs
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê >MN"87U6
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule T+&fUhSy
5. Autogous mixed lymphoyte reaction
-43>?m/a
¶þ¡¢ ÎÊ´ðÌâ n}IGxum8`
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ Se'SDJl=
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ [)s4:V
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷Óᣠ0VtjVz*C7&
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹Øϵ£¿ X5[vQ3^
`1(ED= |
7$Z_'GJ]1C
FEu"
b@v
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ qX5>[qf-
H
Eq{TUTr
x>Q% hl
רҵ¿Î ÃâÒßѧ 4tLdqs
te-xhJ&K
{{Ox%Zm
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê jDb\4QyC
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance .Ji9j[[#D
5. Delayed type hypersensitivity By8SRWs
¶þ¡¢ ÎÊ´ðÌâ ~nU9j"$
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ 5["3[h
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£
AF"7 _
3. ¼òÊöHLAÓëҽѧµÄ¹Øϵ¡£ dv\bkDF4A
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷Óᣠ7Qd$@ m
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷ÓᣠyjL+1_"B
:Q=y'<
o}:x-Y
; >H1A
O)vGIp?f't
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 4%~*}
#W)m({}
]-X6Cl
רҵ¿Î ÃâÒßѧ Gh=I2GSo
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê aq_K,li#w
1. hypersensitivity 2. cluster of differentiation WyatHC
3. adhesion molecules 4. supper antigen 5. split tolerance r6uN6XCM
¶þ¡¢ ÎÊ´ðÌâ wW*7
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ N
? Jy
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ zw15r" R
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ UU>+ b:
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ xA7~"q&u
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ Xrb7.Y0d
7nnF!9JOv
O$6&4p*F.
L#K`F8Wi=
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ Y|r7gy9%
רҵ¿Î ÃâÒßѧ *
rlVE
Ò»¡¢ Ãû´Ê½âÊÍ 8k-]u3
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å [G$ #jUt/O
5. GVHR ;G8H'gM07
¶þ¡¢ ÎÊ´ðÌâ o+=wQ$"tP
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷Óᣠ_?O' A"
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌصãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£
>Vt2@Ee
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌص㡣 \7b, Mz!
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ *V',@NH#Os
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ [5L?#Y
!@Qk=Xkg
oB5\^V$
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ V4jMx[
hJ ^+asr
/jJD
{
רҵ¿Î ÃâÒßѧ d*s*AV
Ò»¡¢Ãû´Ê½âÊÍ }~zDcj_
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å j
H2)8~P
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ &J2U
AmB
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ nu+K
N,3R"
11. »ìºÏÁÜ°Íϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ {H[N|\
Èý¡¢ ÎÊ´ðÌâ Q/?`);
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ X,VI5$
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ k"cMAu.
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà ~xxq.rL"
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ _f@,)n
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ ]'Eg2(wy
D%o(HS\E
^/E'Rf3[A
JR]
elRR
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 9*s8%pL
qX\85dPn@}
*Lrrl
רҵ¿Î ÃâÒßѧ #1$4<o#M
Ò»¡¢Ãû´Ê½âÊÍ ]pe7I
P
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó 3LfF{ED@
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁÜ°Íϸ°ûµÄ±íÃæ±êÖ¾ +I5\`By=
Èý¡¢ ÎÊ´ðÌâ ?9{^gW4|
1. ¼òÊöTÁÜ°Íϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ j;}-x1R
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ \wz^Z{U
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ aB~k8]q.
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ OAq-(_H
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ %%X/
gvaJ
Qc*p+
N+$
k0j4P^d
geK;r0(f
-x6_HibbD
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ `TO Xktj
Ò»¡¢Ãû´Ê½âÊÍ c$[2tZ
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï 46T(1_Xt~
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó ;C*2Djb*n
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ l,Q`;v5|
¶þ¡¢ ÎÊ´ðÌâ -n"f>c_{>
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ YkF LNCg4}
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ JQbaD-
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ n5~Dxk
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ )( 3)^/Xz
*.w6 =}
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ gLt6u|0q
Ò»¡¢ Ãû´Ê½âÊÍ @dK_w'W
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ n+=7u[AZi
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ vh2/d.MO
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© R $<{"b
10¡¢ ÒõÐÔÑ¡Ôñ 4V[(RXc/
¶þ¡¢ ÎÊ´ðÌâ .mrv"k\<
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 >j]Gz-wC
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ EK>x\]O%T
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 qYe`</
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ L8.A|
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. )<J #RgE
P)y2'JKL
G@D8[
x^[0UA]S9
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ByoI+n* U
aTHf+;
z4J\BB
רҵ¿Î ÃâÒßѧ B;Z _'.i,d
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ Z1W
%fT
1. Cytokines 2. adhesion molecules 3. graft versus host reaction ~<IQe-Q5
4. immunologic tolerance 5. Opsonization h3>u[cX%
Èý¡¢ ÎÊ´ðÌâ , =*^XlO=c
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷ÓᣠXH0Vs.w
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ ZrP
8
/>
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ =dKk #*
4. ÃâÒßϵͳɱÉË°Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ 0ZL>-
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ mOjjw_3gq
OI/]Y7D[Oq
~P!=fU)
='Oxy
C_[
d
|tY6+T}
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ ept:<!4
Ak`?,*LM
(Ze\<Y#cv
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ rP6k}
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ +K=RM qM-8
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê Ym]rG
4
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ URh5ajoR%
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û O9N%dir
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö M-!#-l
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð su-0G?c
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖƱ¸ÔÀí¡£ La^Zr,T!
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ &t@ $]m(
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃ濹ԺͱíÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© X5tV Xd
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ 9 771D
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ G<*h,'B
dt>!=<|k
jd+
HIR
a}Jy o!.
wp/x|AV
5kv]k?
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ )4+uM'2%
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ
q,'~=Y5
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ .B$3y#TOb
okW'}@jD
Ò»¡¢ Ãû´Ê½âÊÍ NL ceBok
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß 1T3YFt@&I
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò }M
\G
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô tkix@Q!;\
¶þ¡¢ÎÊ´ðÌâ Ly/5" &HD
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ 495(V(+5
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì Yr:$)ap
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì *\wf(o>Q
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ ,!^w
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ 23UXOY0BW
odq3@
ziO